James Peyer Buys 10,845 Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Director James Peyer acquired 10,845 shares of the firm’s stock in a transaction dated Tuesday, January 11th. The stock was bought at an average price of $5.18 per share, with a total value of $56,177.10. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

James Peyer also recently made the following trade(s):

  • On Tuesday, December 28th, James Peyer bought 11,288 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $5.28 per share, with a total value of $59,600.64.
  • On Thursday, December 23rd, James Peyer acquired 11,000 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $5.27 per share, with a total value of $57,970.00.
  • On Friday, December 17th, James Peyer acquired 117 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $5.29 per share, with a total value of $618.93.

Shares of SNSE stock opened at $5.24 on Friday. The firm has a 50 day moving average price of $6.69 and a two-hundred day moving average price of $8.15. Sensei Biotherapeutics, Inc. has a 12-month low of $4.70 and a 12-month high of $26.50.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Monday, November 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.07). On average, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -1.37 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund raised its position in shares of Sensei Biotherapeutics by 37.2% in the second quarter. New York State Common Retirement Fund now owns 5,396 shares of the company’s stock valued at $53,000 after buying an additional 1,462 shares in the last quarter. Royal Bank of Canada raised its position in shares of Sensei Biotherapeutics by 255.1% in the third quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock valued at $25,000 after buying an additional 1,732 shares in the last quarter. Citigroup Inc. raised its position in shares of Sensei Biotherapeutics by 565.5% in the third quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock valued at $25,000 after buying an additional 2,047 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Sensei Biotherapeutics by 31.1% in the second quarter. Bank of New York Mellon Corp now owns 18,431 shares of the company’s stock valued at $180,000 after buying an additional 4,369 shares in the last quarter. Finally, Morgan Stanley acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at approximately $96,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response.

Featured Story: Risk Tolerance and Your Investment Decisions

Insider Buying and Selling by Quarter for Sensei Biotherapeutics (NASDAQ:SNSE)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.